• 四川大學(xué)華西醫(yī)院老年病科（成都 610041）;

目的 　對(duì)格列喹酮治療糖尿病的相關(guān)臨床研究證據(jù)進(jìn)行綜述。
方法 　運(yùn)用循證醫(yī)學(xué)的基本原理和方法，系統(tǒng)檢索格列喹酮治療糖尿病的相關(guān)臨床研究證據(jù)，并對(duì)證據(jù)質(zhì)量進(jìn)行評(píng)價(jià)。
結(jié)果 　目前關(guān)于格列喹酮治療糖尿病的大多數(shù)臨床研究證據(jù)級(jí)別較低，結(jié)局指標(biāo)多為中間指標(biāo)，缺乏與糖尿病患者預(yù)后密切相關(guān)的臨床終點(diǎn)指標(biāo)研究；缺乏格列喹酮治療糖尿病的衛(wèi)生經(jīng)濟(jì)學(xué)評(píng)價(jià)。
結(jié)論 　格列喹酮在老年伴有腎臟損害的糖尿病患者有其獨(dú)特的優(yōu)勢(shì)。進(jìn)一步開(kāi)展高質(zhì)量、觀察臨床終點(diǎn)指標(biāo)和衛(wèi)生經(jīng)濟(jì)學(xué)指標(biāo)研究將是今后格列喹酮治療糖尿病的研究方向。

引用本文： 李 峻,吳紅梅. 格列喹酮治療糖尿病的循證臨床證據(jù). 中國(guó)循證醫(yī)學(xué)雜志, 2006, 06(9): 690-694. doi: 復(fù)制

1. 李幼平 主編. 循證醫(yī)學(xué). 第1版. 北京: 高等教育出版社; 2003. 20～21.
2. 劉國(guó)良, 趙曉娟, 都建, 等. 糖適平治療2型糖尿病的臨床療效觀察. 遼寧實(shí)用糖尿病雜志, 2004; 12(3): 58～60.
3. 張子文, 吳長(zhǎng)富, 許敏琦. 糖適平對(duì)2型糖尿病患者腎臟保護(hù)作用研究. 現(xiàn)代中西醫(yī)結(jié)合雜志, 2004; 13(4): 488～489.
4. 王素如. 格列喹酮2種片劑治療2型糖尿病的比較. 中國(guó)新藥與臨床雜志, 2000; 19(5): 417～418.
5. 李偉紅, 周雅清. 糖適平治療糖尿病腎功能不全10例療效觀察. 黑龍江醫(yī)藥科學(xué), 2001; 24(3): 40.
6. 龔燕平, 李春霖, 田慧. 格列喹酮治療老年人2型糖尿病療效觀察. 人民軍醫(yī), 2004; 47(l1): 623～625.
7. Nicolai H, Brickl R, Eschey H, et al. Duration of action and Pharmacokinetics of the oral antidiahetic drug gliquidone in patients with non-insulin-dependent (type2) diabetes mellitus. Arzneimittelforschung, 1997; 47(3): 247–252.
8. Guyatt GH, Rennie D, Editors, The Evidence–Based Medicine Working Group. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. AMA Press, Chicago, 2002.
9. Li YP, Chief editor. Evidence-Based Medicine. 1st eds. Beijing: Higher Education Press; 2003. 20–21.
10. Ciccarone A, Cecchetti P, Orsini P, et al. Effects of gliquidone and glibenclamide on metabolic response and insulin receptor interaction in monocytes from patients with type 2 diabetes mellitus. Current Therapeutic Research, Clinical & Experimental, 1999; 60(6): 314–325.
11. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications, 1994; 8(4): 201–203.
12. Harrower AD. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. Diabetes research and clinical practice, 1991; 14(2): s65–67.
13. Harrower AD. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin, 1985; 9(10): 676–680.
14. Nikkil K, Groop L. Glibenclamide and gliquidone in the treatment of non-insulin-dependent diabetes mellitus. Acta medica Scandinavica, 1982; 211(1-2): 13–17.
15. Chou SC, Chen KW, Huang CC, et al. The effects of glurenorm on plasma glucose and lipids in patients with type 2 diabetes mellitus. Chang Gung Med J, 2000; 23(8): 480–484.
16. Nitiyanant W, Sriussadaporn S, Deerochanawong C, et al. The efficacy and safety of gliquidone in Thai diabetics. J Med Assoc Thai, 1997; 80(12): 771–777.
17. Degtiareva II, Lodianaia EV, Opanasiuk ND, et al. The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus. Lik Sprava, 1995; (7-8): 84–87.
18. Podrouzkova B, Krusova D. Combined therapy with insulin/gliquidone (Glurenorm) in type 2 diabetes after treatment failure using oral antidiabetic agents. Vnitr Lek, 1992; 38(10): 963–967.
19. Bonora E, Moghetti P, Querena M, et al. Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone. J Endocrinol Invest, 1992; 15(1): 1-11.
20. Kreze A, Vozar J, Razus P, et al. Multicenter study with gliquidone in type 2 diabetes mellitus. Vnitr Lek, 1991; 37(9–10): 761–767.
21. Liu GL, Zhao XJ, Du J, et al. Clinical observation on the efficacy of glurenorm in the treatment of type 2 diabetes. Liaoning Journal of Practical Diabetology, 2004; 12(3): 58–60.
22. Zhang ZW, Wu CF, Xu MQ. Research on the effect of glurenom in kidney protection of type 2 diabetes. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2004; 12(3): 58–60.
23. Wang SR. Comparison of two tablet types of gliquidone in the treatment of type 2 diabetes. Chinese Journal of New Drugs and Clinical Remedies, 2000; 19(5): 417–418.
24. Li WH, Zhou YQ. Observation on the efficacy of glurenom in the treatment of renal insufficiency caused by diabetes. Heilongjiang Medicine and Pharmacy, 2001; 24(3): 40.
25. Gong YP, Li CL, Tian H. Observation on the efficacy of gliquidone in the treatment of type 2 diabetes in elderly patients. People’s Military Surgeon, 2004; 47(11): 623–625.
  1. 1. 李幼平 主編. 循證醫(yī)學(xué). 第1版. 北京: 高等教育出版社; 2003. 20～21.
  2. 2. 劉國(guó)良, 趙曉娟, 都建, 等. 糖適平治療2型糖尿病的臨床療效觀察. 遼寧實(shí)用糖尿病雜志, 2004; 12(3): 58～60.
  3. 3. 張子文, 吳長(zhǎng)富, 許敏琦. 糖適平對(duì)2型糖尿病患者腎臟保護(hù)作用研究. 現(xiàn)代中西醫(yī)結(jié)合雜志, 2004; 13(4): 488～489.
  4. 4. 王素如. 格列喹酮2種片劑治療2型糖尿病的比較. 中國(guó)新藥與臨床雜志, 2000; 19(5): 417～418.
  5. 5. 李偉紅, 周雅清. 糖適平治療糖尿病腎功能不全10例療效觀察. 黑龍江醫(yī)藥科學(xué), 2001; 24(3): 40.
  6. 6. 龔燕平, 李春霖, 田慧. 格列喹酮治療老年人2型糖尿病療效觀察. 人民軍醫(yī), 2004; 47(l1): 623～625.
  7. 7. Nicolai H, Brickl R, Eschey H, et al. Duration of action and Pharmacokinetics of the oral antidiahetic drug gliquidone in patients with non-insulin-dependent (type2) diabetes mellitus. Arzneimittelforschung, 1997; 47(3): 247–252.
  8. 8. Guyatt GH, Rennie D, Editors, The Evidence–Based Medicine Working Group. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. AMA Press, Chicago, 2002.
  9. 9. Li YP, Chief editor. Evidence-Based Medicine. 1st eds. Beijing: Higher Education Press; 2003. 20–21.
  10. 10. Ciccarone A, Cecchetti P, Orsini P, et al. Effects of gliquidone and glibenclamide on metabolic response and insulin receptor interaction in monocytes from patients with type 2 diabetes mellitus. Current Therapeutic Research, Clinical & Experimental, 1999; 60(6): 314–325.
  11. 11. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications, 1994; 8(4): 201–203.
  12. 12. Harrower AD. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. Diabetes research and clinical practice, 1991; 14(2): s65–67.
  13. 13. Harrower AD. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin, 1985; 9(10): 676–680.
  14. 14. Nikkil K, Groop L. Glibenclamide and gliquidone in the treatment of non-insulin-dependent diabetes mellitus. Acta medica Scandinavica, 1982; 211(1-2): 13–17.
  15. 15. Chou SC, Chen KW, Huang CC, et al. The effects of glurenorm on plasma glucose and lipids in patients with type 2 diabetes mellitus. Chang Gung Med J, 2000; 23(8): 480–484.
  16. 16. Nitiyanant W, Sriussadaporn S, Deerochanawong C, et al. The efficacy and safety of gliquidone in Thai diabetics. J Med Assoc Thai, 1997; 80(12): 771–777.
  17. 17. Degtiareva II, Lodianaia EV, Opanasiuk ND, et al. The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus. Lik Sprava, 1995; (7-8): 84–87.
  18. 18. Podrouzkova B, Krusova D. Combined therapy with insulin/gliquidone (Glurenorm) in type 2 diabetes after treatment failure using oral antidiabetic agents. Vnitr Lek, 1992; 38(10): 963–967.
  19. 19. Bonora E, Moghetti P, Querena M, et al. Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone. J Endocrinol Invest, 1992; 15(1): 1-11.
  20. 20. Kreze A, Vozar J, Razus P, et al. Multicenter study with gliquidone in type 2 diabetes mellitus. Vnitr Lek, 1991; 37(9–10): 761–767.
  21. 21. Liu GL, Zhao XJ, Du J, et al. Clinical observation on the efficacy of glurenorm in the treatment of type 2 diabetes. Liaoning Journal of Practical Diabetology, 2004; 12(3): 58–60.
  22. 22. Zhang ZW, Wu CF, Xu MQ. Research on the effect of glurenom in kidney protection of type 2 diabetes. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2004; 12(3): 58–60.
  23. 23. Wang SR. Comparison of two tablet types of gliquidone in the treatment of type 2 diabetes. Chinese Journal of New Drugs and Clinical Remedies, 2000; 19(5): 417–418.
  24. 24. Li WH, Zhou YQ. Observation on the efficacy of glurenom in the treatment of renal insufficiency caused by diabetes. Heilongjiang Medicine and Pharmacy, 2001; 24(3): 40.
  25. 25. Gong YP, Li CL, Tian H. Observation on the efficacy of gliquidone in the treatment of type 2 diabetes in elderly patients. People’s Military Surgeon, 2004; 47(11): 623–625.